Design-build services for major facility expansion creates drought-resilient drinking water supplyDALLAS, Nov. 18, 2024 /PRNewswire/ -- The McCarthy-Jacobs (NYSE:J) joint venture was selected to design and build the Torrance Groundwater Desalter Expansion, a critical component of Water Replenishment District (WRD) of Southern California's Brackish Groundwater Reclamation Program and its larger "WIN 4 ALL" initiative. The desalination expansion project will treat salt water in the West Coast Groundwater Basi ...

Kenorland Announces Termination of Joint Venture Exploration Agreement at the Chicobi Project, QuebecNovember 18, 2024 7:30 AM EST | Source: Kenorland Minerals Ltd.Vancouver, British Columbia--(Newsfile Corp. - November 18, 2024) - Kenorland Minerals Ltd. (TSXV: KLD) (OTCQX: KLDCF) (FSE: 3WQ0) ("Kenorland" or the "Company") announces that Sumitomo Metal Mining Canada Ltd. ("Sumitomo") has elected to withdraw from the Earn-in and Joint Venture Exploration Agreement dated February 15, 2019 ("JVE ...

Core Insights - The Joint Corp. (JYNT) experienced a 2.7% decline in share price following the release of its third-quarter 2024 results, primarily due to high general and administrative expenses and impairment-related charges, although this was mitigated by increased system-wide sales driven by improved royalty fees, advertising fund revenues, and software fees [1][4]. Financial Performance - Adjusted earnings per share for JYNT were reported at 4 cents, aligning with the Zacks Consensus Estimate, and showing improvement from an adjusted loss of 5 cents per share in the previous year [2]. - Total revenues increased by 2% year over year to $30.2 million, surpassing the consensus estimate by 5.5% [2]. - Revenue from company-owned or managed clinics decreased by 1.9% year over year to $17.5 million, while royalty fees rose by 10.2% to $7.9 million [3]. - Advertising fund revenues increased by 9.6% year over year to $2.2 million, and software fees improved by 10% to $1.4 million [3]. - Franchise fees fell by 7.5% year over year to $0.7 million [3]. Cost Structure - Total cost of revenues rose by 8.4% year over year to $2.8 million, attributed to higher regional developer royalties and commissions [4]. - General and administrative expenses increased by 2.7% year over year to $20.8 million, while total selling, general, and administrative costs decreased by 0.4% year over year to $26.8 million [4]. Net Loss and Cash Flow - The company reported a net loss of $3.2 million, which is wider than the net loss of $0.7 million in the same quarter last year, primarily due to losses from disposition or impairment [4]. - For the first nine months of 2024, JYNT generated net cash from operations of $5.3 million, a decline of 53.2% from the prior-year period [7]. Sales and Clinic Count - System-wide sales increased by 8% year over year to $129.3 million [5]. - As of September 30, 2024, the total clinic count was 963, which was below the Zacks Consensus Estimate of 975, with franchised clinics totaling 838, also lower than the consensus mark of 864 [5]. Financial Position - JYNT ended the third quarter with cash and cash equivalents of $20.7 million, reflecting a 14.2% increase from the end of 2023 [6]. - Total assets decreased by 8.7% from the end of 2023 to $79.6 million, while total equity declined by 17.3% to $20.5 million [6]. Guidance - The company revised its guidance for system-wide sales to a range of $525-$535 million, down from the previous estimate of $530-$545 million, and expects to open 55-60 franchised clinics, reduced from the earlier forecast of 60-75 [8].

Singapore, Nov. 12, 2024 (GLOBE NEWSWIRE) -- SIMPPLE Ltd. (NASDAQ: SPPL) (“SIMPPLE” or “the Company”), a leading technology provider and innovator in the integrated facilities management sector, today announced it had commenced paid trials of the first platform successfully merging a full menu of smart building automation functions with a diverse array of global compliance capabilities. The platform, developed via a confidential joint venture between SIMPPLE and Denmark-based consulting and technology firm ...

TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD”) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, announces that through the completion of a private placement (the “Acquisition”), ThreeD and Sheldon Inwentash (the “Joint Actor”) acquired ownership and control of an aggregate of 9,000,000 common shares (the “Subject Shares”) and 9,000,000 common share purchase w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _________________ Commission file number: 001-36724 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware ...

The Joint Corp. (JYNT) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced a loss of $0.06, delivering a surprise of -500%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.The Joint, which belongs to the Zacks Me ...

Financial Performance - Revenue for Q3 2024 increased by 2% to $30.2 million compared to $29.5 million in Q3 2023[3] - Net loss for Q3 2024 was $3.2 million, including a $3.8 million loss on disposition or impairment, compared to a net loss of $716,000 in Q3 2023[6] - Adjusted EBITDA for Q3 2024 was $2.4 million, down from $2.9 million in Q3 2023[6] - Total revenues for the three months ended September 30, 2024, were $30,198,490, compared to $29,473,949 for the same period in 2023, reflecting an increase of approximately 2.5%[28] - Net loss for the three months ended September 30, 2024, was $(3,165,139), compared to a loss of $(716,273) for the same period in 2023, indicating a significant increase in losses[28] - Net income for the nine months ended September 30, 2024, was a loss of $5,814,558 compared to a profit of $1,289,402 for the same period in 2023[29] - EBITDA for the nine months ended September 30, 2024, was a loss of $1,426,645, compared to $8,747,122 for the same period in 2023[30] - Adjusted EBITDA for the nine months ended September 30, 2024, was $8,065,873, slightly down from $8,165,066 in the same period of 2023[30] Sales and Growth - System-wide sales grew by 8% to $129.3 million, with system-wide comp sales reported at 4%[3] - The company expects system-wide sales for 2024 to be between $525 million and $535 million, adjusted from previous guidance[11] - System-wide comp sales for clinics open 13 months or more are projected to be between 3% and 4% for 2024[11] - New franchised clinic openings are expected to be between 55 and 60, adjusted from earlier estimates[11] Assets and Liabilities - Total current assets increased to $55,170,858 as of September 30, 2024, up from $44,335,538 as of December 31, 2023, representing a growth of approximately 24.5%[23] - Total liabilities decreased to $59,123,273 as of September 30, 2024, from $62,378,977 as of December 31, 2023, a reduction of about 5.4%[24] - Total assets decreased to $79,598,822 as of September 30, 2024, from $87,150,859 as of December 31, 2023, a decline of approximately 8.7%[25] - Goodwill decreased to $4,237,945 as of September 30, 2024, from $7,352,879 as of December 31, 2023, a reduction of about 42.5%[23] Cash Flow and Expenses - Unrestricted cash was $20.7 million at September 30, 2024, compared to $18.2 million at December 31, 2023[9] - Cash and cash equivalents rose to $20,737,769 as of September 30, 2024, compared to $18,153,609 as of December 31, 2023, marking an increase of about 14.2%[23] - Accounts receivable increased to $4,295,663 as of September 30, 2024, from $3,718,924 as of December 31, 2023, a rise of approximately 15.5%[23] - Selling, general, and administrative expenses totaled $26,755,892 for the three months ended September 30, 2024, slightly down from $26,862,973 in the same period of 2023[28] - The company reported a basic loss per share of $(0.05) for the three months ended September 30, 2024, compared to earnings of $0.09 for the same period in 2023[28] - Net cash provided by operating activities decreased to $5,284,936 for the nine months ended September 30, 2024, down from $11,294,757 in the prior year[29] - Net cash used in investing activities was $(527,294) for the nine months ended September 30, 2024, compared to $(4,883,148) in the previous year[29] - The company incurred stock compensation expense of $1,475,710 for the nine months ended September 30, 2024, compared to $1,209,296 in the prior year[30] - The company recognized deferred revenue of $(1,504,305) for the nine months ended September 30, 2024, compared to $(551,226) in the previous year[29] Strategic Initiatives - The company is committed to refranchising efforts and improving clinic economics to drive growth and profitability[3] - The company reported a significant increase in payroll liabilities to $2,621,327 for the nine months ended September 30, 2024, from $1,844,943 in the prior year[29] - The company reported a net loss on disposition or impairment of $5,602,641 for the nine months ended September 30, 2024, compared to $1,114,738 in the previous year[29]

Core Viewpoint - Gauzy Ltd. and Research Frontiers Inc. have announced a partnership, with Ferrari selecting Gauzy as a strategic supplier to incorporate Suspended Particle Device (SPD) technology into its vehicles for mass production [1][2] Company Overview - Gauzy Ltd. is a leader in light and vision control technology, headquartered in Tel Aviv, Israel, with a global presence in over 30 countries [8] - Research Frontiers Inc. develops and licenses SPD-Smart light-control film technology, which allows for precise control of shading in glass and plastic products [9] Partnership and Market Opportunities - The partnership with Ferrari marks the first mass production use of SPD technology in one of its prestigious models, indicating significant growth potential for smart glass applications in automotive, architectural, and aeronautical sectors [2][3] - The SPD smart glass market is projected to grow at a compound annual growth rate (CAGR) of 9.9% from 2024 to 2031, reaching a market value of $13.4 billion by the end of 2031 [3] Industry Applications - SPD technology is gaining traction in the automotive and aeronautics industries, providing benefits such as comfort, safety, aesthetics, energy efficiency, and thermal comfort [3][5] - Major automotive manufacturers, including McLaren, Mercedes, and Cadillac, have already integrated SPD smart glass into their vehicle designs, with expectations for wider adoption in mass-market cars [4] - In aeronautics, SPD technology is being incorporated into commercial airplanes, business jets, and helicopters to enhance passenger comfort and light control [5] Technology Features - SPD technology utilizes specially-engineered nanoparticles to control light dynamically, allowing up to 99% blocking of visible light, increasing head space in vehicles by at least 5 centimeters, and extending driving ranges in electric vehicles [6]

Company Overview - Helium Evolution Incorporated (HEVI) is a Canadian-based helium exploration company focused on developing assets in southern Saskatchewan, holding the largest helium land rights position in North America among publicly-traded companies with over five million acres under permit [6] Recent Exploration Activities - HEVI has provided an update on its exploration activities, including the results of a joint well (7-2 Well) where it holds a 20% working interest alongside North American Helium Inc. (NAH), which has reached total depth and the cased hole portion has been suspended for future exploration [2][4] - NAH plans to drill another joint well (10-1 Well) in the Mankota area, anticipated to spud in the coming days, as part of a development plan for up to nine wells in the area [3][4] Financial Position - The estimated total cost for HEVI's share in the 10-1 Well is approximately $0.4 million, supported by a strong working capital position of $4.7 million as of June 30, 2024, indicating the company's capability to fund its exploration initiatives [4] Strategic Commitment - HEVI's continued investment in the Mankota area underscores its commitment to expanding its footprint in the helium sector, aiming to become a leading supplier of sustainably-produced helium for the growing global market [4][6]